Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.63 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.63 |
| ▸ | CASP3 | P42574 | 1/20 | 0.59 |
| ▸ | TSHR | P16473 | 1/20 | 0.57 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.57 |
| ▸ | ACHE | P22303 | 4/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | MAOB | P27338 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL751414 | 0.81 | ALDH1A1 (0.54) | TDP1L3MBTL1ALDH1A1MAPTRAB9A | |
| SCHEMBL45050 | 0.81 | TDP1 (0.86) | TDP1L3MBTL1CASP3TSHRMAPK1 | |
| SCHEMBL30371663 | 0.81 | TDP1 (0.86) | TDP1L3MBTL1CASP3TSHRMAPK1 | |
| SCHEMBL11211597 | 0.80 | ALDH1A1 (0.52) | TDP1L3MBTL1ALDH1A1MAPTRAB9A | |
| SCHEMBL916601 | 0.79 | TDP1 (0.96) | TDP1L3MBTL1CASP3TSHRMAPK1 | |
| SCHEMBL13442856 | 0.78 | CASP3 (0.81) | TDP1L3MBTL1CASP3TSHRMAPK1 | |
| SCHEMBL12134374 | 0.78 | ALDH1A1 (0.48) | TDP1L3MBTL1CASP3ALDH1A1MAPT | |
| SCHEMBL8434811 | 0.78 | TDP1 (1.00) | TDP1L3MBTL1CASP3ACHE | |
| SCHEMBL31035964 | 0.78 | TDP1 (1.00) | TDP1L3MBTL1CASP3ACHE | |
| SCHEMBL5093425 | 0.78 | TDP1 (1.00) | TDP1L3MBTL1CASP3ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10806794-B2 | Protease inhibitors having enhanced features | NEKTAR THERAPEUTICS (US) | 2020-10-20 | — | — | US | disclosed |
| US-20170028077-A1 | PROTEASE INHIBITORS HAVING ENHANCED FEATURES | NEKTAR THERAPEUTICS | 2017-02-02 | — | — | US | disclosed |
| US-20170028077-A1 | PROTEASE INHIBITORS HAVING ENHANCED FEATURES | NEKTAR THERAPEUTICS | 2017-02-02 | — | — | US | disclosed |
| US-20120108501-A1 | Protease Inhibitors | NEKTAR THERAPEUTICS (US) | 2012-05-03 | — | — | US | disclosed |
| US-20120108501-A1 | Protease Inhibitors | NEKTAR THERAPEUTICS (US) | 2012-05-03 | — | — | US | disclosed |
| US-20110195940-A1 | Protease Inhibitors Having Enhanced Features | NEKTAR THERAPEUTICS (CA) | 2011-08-11 | — | — | US | disclosed |
| US-20110195940-A1 | Protease Inhibitors Having Enhanced Features | NEKTAR THERAPEUTICS (CA) | 2011-08-11 | — | — | US | disclosed |
| WO-2010033219-A2 | PROTEASE INHIBITORS HAVING ENHANCED FEATURES | NEKTAR THERAPEUTICS (US) | 2010-03-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10806794-B2 | Protease inhibitors having enhanced features | SERPINB1, SPINT2, TMPRSS15 | TDP1 989/4885L3MBTL1 3933/4885CASP3 633/4885 |
| US-20170028077-A1 | PROTEASE INHIBITORS HAVING ENHANCED FEATURES | SERPINB1, SPINT2, TMPRSS15 | TDP1 989/4885L3MBTL1 3933/4885CASP3 633/4885 |
| US-20110195940-A1 | Protease Inhibitors Having Enhanced Features | CYP3A43, HPN, ANPEP | TDP1 1783/4885L3MBTL1 3745/4885CASP3 122/4885 |
| US-20120108501-A1 | Protease Inhibitors | DNPEP, ADAM17, PREP | TDP1 1780/4885L3MBTL1 1444/4885CASP3 283/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.